106 results about "Immunolabeling" patented technology

Infectious cDNA clones of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are provided. Further provided are cDNA clones comprising genetic mutations. Also provided are vaccines comprising cDNAs, including genetically and immunologically marked vaccines for North American PRRSV.

The present invention provides labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling reagents have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Typically, the labeling reagent is an anti-Fc Fab or Fab′ fragment that was generated by immunizing a goat or rabbit with the Fc fragment of an antibody. The present invention provides for discrete subsets of labeling reagent and immuno-labeled complexes that facilitate the simultaneous detection of multiple targets in a sample wherein the immuno-labeled complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets.

The invention relates to a preparation method and an application of a spectinomycin fast time-resolved fluoroimmunoassay quantitative detection test strip. The test strip consists of a Fusion5 membrane, a nitrocellulose membrane and water absorption paper; quick and fast quantitative detection is performed on the antigen to be detected by taking a time-resolved fluorescent microsphere as an immune marker based on the principle of competition law.

The invention relates to preparation for a cadmium antimonide quantum dot immune marker and a detection method for electrochemical sandwich immune, having the signal amplification function. Through the reaction of silicon dioxide particle and reacting ATPS, an active amido group is modified on the surface of the silicon dioxide particle under room temperature. The silicon dioxide particle is then reacted with carboxyl on the surface of a quantum dot to form a silicon dioxide microsphere with the surface modified with the quantum dot. The silicon dioxide microsphere after being modified is further modified with a second antibody on the surface of the quantum dot under the actions of EDC and NHS, and a cadmium antimonide quantum dot immune marker is obtained. The detection method for the electrochemical sandwich immune utilizes anti-AFP to modify Fe3O4 magnetic nano-microsphere, thereby Si / QD / Ab2 is modified on magnetic particles, and then electrochemical determination is carried out. Because the surface of the marker is rich in the quantum dots, the amount of the quantum dot loaded in a single sandwich immune process is greatly increased, dissolving-out voltammetry detection signals of an anode are amplified, and the sensitivity of low-concentration biomolecule detection is greatly enhanced.

In various embodiments, the present application teaches methods and compositions for tissue clearing in which whole organs and bodies are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches PACT, a protocol for passive tissue clearing and immunostaining of intact organs. In other embodiments, the present application teaches RIMS, a refractive index matching media for imaging thick tissue. In yet other embodiments, the application teaches PARS, a method for whole-body clearing and immunolabeling.

The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research.

The invention relates to a combined assay kit for premature birth of a pregnant woman and fetal membrane premature rupture, which comprises a premature birth and fetal membrane premature rupture immunochromatographic assay test strip or comprises a premature birth immunochromatographic assay test strip and a fetal membrane premature rupture immunochromatographic assay test strip. More preferably, the combination mat and the nitrocellulose membrane of the premature birth immunochromatographic assay test strip are respectively provided with a premature birth assay immunolabelling antibody and a premature birth assay antibody; the combination mat and the nitrocellulose membrane of the fetal membrane premature rupture immunochromatographic assay test strip are respectively provided with a fetal membrane premature rupture assay immunolabelling antibody and a fetal membrane premature rupture assay antibody, or the immunolabelling antibodies and the antibodies are respectively coated onto the combination mats and the nitrocellulose membranes of the premature birth and fetal membrane premature rupture immunochromatographic assay test strip. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is capable of simultaneously diagnosing the premature birth and the fetal membrane premature rupture through primary sampling, is simple and convenient in application, and further, is capable of improving the accuracy of premature birth diagnosis. A powerful basis is provided for the next accurate treatment by combined assay results. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is suitable for popularization and application in a large scale.

The invention relates to the field of immune marking vaccines and in particular relates to construction and an application of recombinant peste des petits ruminants virus expressing fused exogenous epitope N protein.

The invention relates to a magnetic sensing identification method for high-flux multi-channel low-abundance biomolecules, and belongs to the technical field of biomolecule identification. The invention mainly aims at an immunolabelling biomolecule detection, monitoring and identification method based on systems such as antigens-antibodies, cell factors-cell factor acceptors, bioactive peptides-acceptors, biotin-avidin and chiral molecules. A biomolecule probe and detection system consists of superparamagnetic particles and high-performance magnetic sensors. The magnetic sensing identification method can be applied to the application fields of biology, medicines, food safety and the like, and can be used for biomolecule identification, detection and monitoring, clinical disease diagnose, food safety detection and virus and germ detection.

The invention provides a system for predicting prognosis of gastric cancer of subjects. The system comprises: a data acquisition module, which is used for acquiring clinical characteristic data of thesubjects, immune marker characteristic data of the subjects and protein expression data of the subjects; a data processing module, which is used for further processing the data acquired in the data acquisition module; and a module for calculating the prognosis risk of the gastric cancer of the subjects, wherein the module utilizes the data processed in the data processing module to calculate theprognosis risk values of the gastric cancer of the subjects, and groups the subjects based on the risk values. According to the system and a method provided by the invention, eight characteristics, including five immunomarkers (CD3, CD4, PDL1, PAX5, and GZMB), an EMT protein marker (CDH1) and two clinical characteristics (pTNM and age), are selected to develop the system and the method that can significantly improve prognostic ability of gastric cancer patients. The system and the method may be applicable to patients with or without neoadjuvant chemotherapy and exhibit predicted values, and the patients may benefit from post-operative adjuvant chemotherapy.

The invention belongs to the technical field of clinical medical pathology and in particular relates to a p16INK4a immunolabeling color-developing kit for cervical liquid-based cells. The kit comprises a p16INK4a antigen preservation solution, a first antibody, a second antibody, a DAB (Diaminobenzidine) color-developing solution, an endogenous peroxidase blocking agent, confining liquid, a buffering solution, a positive reference substance and a negative reference substance. The kit provided by the invention has strong specificity; an antigen and antibody specific combination type dyeing method is utilized and the defect that the specificity of non-specific Papanicolaou staining and naked-eye appearance judgment of current liquid-based cytology are overcome.

The embodiment of the invention discloses a micro-fluidic chip based on a magnetic bead coated antibody and a method for capturing cardiac markers. The micro-fluidic chip based on the magnetic bead coated antibody and the method for capturing cardiac markers are applied to the field of immunomagnetic bead coated binding antibodies, and prevent coated antibodies from being redissolved in a fluid system or being captured by antigens in fluid and disengaged from a base material. The micro-fluidic chip comprises a sample injection chamber, a Y-shaped structure channel and recycling chambers. The Y-shaped structure channel comprises a funnel-shaped channel at the upper portion and a columnar channel at the lower portion. An immunolabelling module is arranged at the bottom of the funnel-shaped channel. A blood filtering module is arranged at the upper portion of the immunolabelling module. The bottom end of the columnar channel at the lower portion is forked to form a pair of parallel immunity channels. The tail end of each immunity channel is connected with one recycling chamber. The columnar channel is provided with an upper cavity and a lower cavity. The upper cavity is a strong magnetism cavity, and the lower cavity is a quality control cavity.

The invention discloses an NTx (Naltrexone) detection test strip. The NTx detection test strip comprises a chromatography membrane and a conjugate pad; an immunolabelled NTx antibody and an immunolabelled first antibody are loaded on the conjugate pad; the chromatography membrane is provided with an NTx protein covered detection line and a second antibody covered colorimetric line along a liquid chromatography direction. When a sample is detected, the colorimetric line correspondingly displays the chroma of specific protein concentration after the second antibody is specifically combined withthe first antibody; NTx protein on the detection line and the NTx protein in the sample are competitively combined with the immunolabelled NTx antibody and the color developing depth of the detectionline and the colorimetric line is directly compared so that semi-quantitative detection of the NTx protein is realized. The invention discloses a preparation method of the NTx detection test strip; the preparation method is used for preparing an NTx protein semi-quantitative detection test strip which is rapid and sensitive in detection and does not depend on an instrument. The invention disclosesan NTx detection kit; the NTx detection kit comprises the NTx detection test strip and can provide effective information for early diagnosis and treatment of osteoporosis.

The present invention provides labeling reagents and methods for labeling primary antibodies and for detecting a target in a sample using an immuno-labeled complex that comprises a target-binding antibody and one or more labeling reagents. The labeling reagents comprise monovalent antibody fragments or non-antibody monomeric proteins whereby the labeling proteins have affinity for a specific region of the target-binding antibody and are covalently attached to a label. Typically, the labeling reagent is an anti-Fc Fab or Fab′ fragment that was generated by immunizing a goat or rabbit with the Fc fragment of an antibody. The present invention provides for discrete subsets of labeling reagent and immuno-labeled complexes that facilitate the simultaneous detection of multiple targets in a sample wherein the immuno-labeled complexes are distinguished by i) a ratio of label to labeling reagent, or ii) a physical property of said label, or iii) a ratio of labeling reagent to said target-binding antibody, or iv) by said target-binding antibody. This is particularly useful for fluorophore labels that can be attached to labeling reagents and subsequently immuno-labeled complexes in ratios for the detection of multiple targets.

The invention discloses a recombinant strain for Brucella abortus provided with an immune label. The recombinant strain for the Brucella melitensis provided with the immune label is a strain obtained by killing encoding genes of perosamine synthetase in the Brucella abortus. Compared with an original strain, the obtained strain has lower virulence, and can be used as a vaccine to immunize animals without killing the genes. By utilization of the strain to immunize a mouse, immunoreaction states different from those of the standard strain and the prior vaccine strain can be generated in the body of the mouse, and sicken animals can be identified from immune animal groups by immunological detection of serum of the animals. The modification of the brucelliasis vaccine and the research of a diagnosis and identification agent have important significance in developing a brucelliasis gene deletion marker vaccine and a matched diagnosis and identification agent and promoting the elimination and purification of brucelliasis of the animals all over the world.

The invention relates to a construction method of an immortalized telocytes system. The construction method comprises the following steps: (1) digesting shorn off mouse lung tissue block in type-II collagenase, carrying out filtering and centrifuging, collecting cyte precipitate, culturing the cyte precipitate in a culture medium, after fibrocytes are attached to a wall, transferring supernate to another culture dish, culturing for 12 hours, then changing liquid, and continuing culturing for 3-5 days; (2) taking a trace spearhead as a cyte scraper to scrape off the fibrocytes, and after scraping off the fibrocytes repeatedly, observing a specificity structure telopode and identifying telocytes by an immune marker; and (3) taking the telocytes as host cells, infecting the host cells by using a retroviral vector which contains SV-40-large tumor antigen, and carrying out passage, screening and identifying. Even if the immortalized telocytes system is cultured to the 50th generation, the state is still stable, and therefore, the problem that the purity and the stability of the telocytes cannot be guaranteed by repeated separation and extraction in the prior art.

This invention discloses to a kind of immunofluorescence mark reagent box. It is a reagent box applied for the aspects of immunity mark which uses the green fluorescence protein (GFP) as the indicator, the staphylococcus protein A (SPA) as the antibody. It also discloses the preparation method of the reagent. This invention can applied wide range in the field such as the immunity fluorescence mark, immunity histochemistry, biochemistry analysis, antibody test, protein chip and so on. It can replace the exist product efficiently, its operation is more simple, stability, delicacy and reliability, it is especially the same with the high flux analysis which analyze by the fluorescence analysis instrument.

In various embodiments, the present application teaches methods and compositions for tissue clearing in which whole organs and bodies are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches PACT, a protocol for passive tissue clearing and immunostaining of intact organs. In other embodiments, the present application teaches RIMS, a refractive index matching media for imaging thick tissue. In yet other embodiments, the application teaches PARS, a method for whole-body clearing and immunolabeling.

In various embodiments, the present application teaches methods and kits for clearing and optionally subsequently visualizing tissue containing bone. In some embodiments, the method includes serially incubating cleared bone in refractive index matching solutions with progressively higher refractive indexes. In some embodiments, the methods teach immunolabeling and / or staining tissue containing bone and optionally visualizing the immunolabeled and / or stained tissue containing bone.

The invention relates to a preparation method and application of a test strip for fast time-resolved fluorescent immunochromatography quantitative detection of amantadine. The test strip comprises three parts such as a Fusion 5 membrane, a cellulose nitrate membrane and water absorbent paper. According to the principle of the competition law, a time-resolved fluorescent microsphere is taken as an immune marker for accurate and fast quantitative detection of an antigen to be detected.

The invention provides a silica fluorescent immunolabeled probe based on fluorescence resonance energy transfer as well as a preparation method and application of the silica fluorescent immunolabelledprobe. The preparation method comprises the steps of using mesoporous silica nanoparticles as matrix, and constructing a fluorescence resonance energy transfer system (RB-BODIPY-FRET) by doping rhodamine B and BODIPY. The fluorescent labeling probe is coupled by using a sodium periodate oxidation antibody, so that a reliable basis is provided for the super-sensitive detection and immunoassay of nano-drug carriers. Compared with the prior art, the silica fluorescent immunolabeling probe is prepared by means of codoping of fluorescent dyes, i.e., the BODIPY and the rhodamine B, and fluorescenceresonance energy transfer occurs between the two fluorescent dyes, so that the fluorescence intensity is increased, and quenching is reduced; the fluorescent labeled probe is coupled by using the sodium periodate oxidation antibody, so that the coupling efficiency is improved, and the influence of a cross-linking agent on the activity of the antibody is eliminated.

The invention relates to a biotinylated liposome used for detecting pancreas cancer marker REG1A. The biotinylated liposome used for detecting pancreas cancer marker REG1A comprises coated reporter DNA fragments, and PEG-200 surface modified biotin; according to the preparation method, DPPC, cholesterol, DSPE-PEG2000, DSPE-PEG2000-biotin film dispersion method is adopted to prepare the biotinylated liposome used for coating reporter DNA fragments, and the biotinylated liposome is taken as an immunolabelling biosensor. The invention also relates to a method used for detecting pancreas cancer marker REG1A based on the biotinylated liposome. The method comprises following steps: an ELSA plate is coated with REG1A murine monoclonal antibodies, a REG1A protein sample to be detected is added, reactions with REG1A rabbit source polyclonal antibodies, biotinylated goat anti rabbit IgG, and avidin are carried out respectively, at last the biotinylated liposome of an optimized concentration is added, fluorescence quantitative LAMP amplification is carried out, and the concentration of the REG1A protein is calculated based on amplification results. According to the preparation method, immunization LAMP reaction is combined with immunoliposome nano-particles, so that high sensitivity detection of pancreas cancer marker REG1A is realized, stability is high, cost is low, and the specificityis high.

This invention discloses using SPR technology to simultaneously and qualitatively detect the presence of respiratory tract viruses-related immunological markers in a serum sample, which can be used for the diagnosis of respiratory tract infections. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antigens used to detect the respective respiratory tract viruses-related immunological markers (antibodies) in blood for the diagnosis of respiratory tract infections.

The invention relates to a preparation method and application of a quick test strip for testing chloramphenicol by adopting time-resolved fluorescence lateral flow immunoassay quantitative testing. The test strip is composed of a Fusion5 membrane, a nitrocellulose membrane and water absorption paper, according to the competition law principle, time-resolved fluorescence microspheres are taken as an immune marker, and accurate and quick quantitative testing can be conducted on a to-be-tested antigen.